Acadia Pharmaceuticals: Pay

Acadia Pharmaceuticals paid its one named executive on file $0 in FY2023 (Dec).

Pay of each named executive

Thomas Garner
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
2 years

CEO pay against the pay peers

In FY2024 (Dec), the median CEO pay of the 8 peers with pay on file was $10.5M. The CEO of Acadia Pharmaceuticals was paid $7.6M, 28% below the median.

  1. 1Supernus Pharmaceuticals
  2. 2Jazz Pharmaceuticals
  3. 3Ionis Pharmaceuticals
  4. 4INSMED
  5. 5Alkermes plc.
  6. 6Neurocrine Biosciences
  7. 7Acadia Pharmaceuticals
  8. 8PTC Therapeutics
  9. 9Sarepta Therapeutics
  10. 10Amicus TherapeuticsNot disclosed
  11. 11Apellis PharmaceuticalsNot disclosed
  12. 12Axsome TherapeuticsNot disclosed
  13. 13Biocryst PharmaceuticalsNot disclosed
  14. 14Blueprint MedicinesNot disclosed
  15. 15Corcept TherapeuticsNot disclosed
  16. 16ExelixisNot disclosed
  17. 17Intra-Cellular TherapiesNot disclosed
  18. 18Pacira BioSciencesNot disclosed
  19. 19Sage TherapeuticsNot disclosed
  20. 20UltragenyxNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.